These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 19238551)

  • 21. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
    Larsen FO; Markussen A; Nielsen D; Colville-Ebeling B; Riis LB; Jensen BV
    Oncology; 2017; 93(3):191-196. PubMed ID: 28531891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
    Assenat E; Ychou M
    Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
    Taniguchi H; Komori A; Narita Y; Kadowaki S; Ura T; Andoh M; Yatabe Y; Komori K; Kimura K; Kinoshita T; Muro K
    Jpn J Clin Oncol; 2016 Mar; 46(3):228-33. PubMed ID: 26759349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biotherapy in colorectal cancer].
    Des Guetz G
    J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
    Wang JX; Wu HL; Zhu M; Zhou R
    Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and advancing treatments for metastatic colorectal cancer.
    Sanz-Garcia E; Grasselli J; Argiles G; Elez ME; Tabernero J
    Expert Opin Biol Ther; 2016; 16(1):93-110. PubMed ID: 26549053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
    Normanno N; Tejpar S; Morgillo F; De Luca A; Van Cutsem E; Ciardiello F
    Nat Rev Clin Oncol; 2009 Sep; 6(9):519-27. PubMed ID: 19636327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
    Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
    Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted biotherapy in metastatic colorectal carcinoma: Current practice.
    Cacheux W; Le Tourneau C; Baranger B; Mignot L; Mariani P
    J Visc Surg; 2011 Feb; 148(1):12-8. PubMed ID: 21277276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Targeted therapies for metastatic colorectal cancer].
    Kito Y; Yamazaki K
    Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
    Kajitani T; Makiyama A; Arita S; Shimokawa H; Oda H; Shirakawa T; Baba E; Esaki T
    Anticancer Res; 2017 Nov; 37(11):6459-6468. PubMed ID: 29061833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies in the treatment of advanced colorectal cancer.
    Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
    Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
    Temraz S; Mukherji D; Shamseddine A
    World J Gastroenterol; 2014 Feb; 20(8):1993-2004. PubMed ID: 24616571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.